Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05857566

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Conditions: Drug-induced Weight Gain

Sex: All
Ages: 18 Years – 50 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 24
Sponsor: Response Pharmaceuticals

Location: Nucleus Network Saint Paul Minnesota

Summary

This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.

Eligibility Criteria

Inclusion Criteria: * A glycated hemoglobin (HbA1c) level of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05857566). StuddyBuddy aggregates publicly available trial information.